FutureFuel Releases Second Quarter 2022 Results
Source: Nasdaq GlobeNewswire / 08 Aug 2022 16:29:11 America/New_York
FutureFuel Second Quarter Net Loss of $3.1 Million
Reports Net Loss of $3.1 Million or $0.07 per Diluted Share, and Adjusted EBITDA of $18.7 Million
CLAYTON, Mo., Aug. 08, 2022 (GLOBE NEWSWIRE) -- FutureFuel Corp. (NYSE:FF) (“FutureFuel”), a manufacturer of custom and performance chemicals and biofuels, today announced financial results for the second quarter ended June 30, 2022.
Second quarter 2022 Financial Highlights (all comparisons are with the second quarter of 2021)
- Revenues were $117.8 million, up 59% from $74.1 million
- Adjusted EBITDA was $18.7 million, up from $4.7 million (see reconciliation table below)
- Net loss was $3.1 million, or $0.07 per diluted share, down from net income of $3.5 million, or $0.08 per diluted share.
Six months 2022 Financial Highlights (all comparisons are with the first half of 2021)
- Revenues were $160.1 million, up 38% from $115.6 million
- Adjusted EBITDA was $20.8 million, up from ($3.2) million (see reconciliation table below)
- Net loss was $15.5 million, or $0.35 per diluted share, down from net loss of $5.3 million, or $0.12 per diluted share.
“At the time of the release of our First Quarter 2022 results, we reported that our biodiesel business was dealt a blow when unprecedented volatility towards the expiry of the New York Mercantile Exchange May heating oil contract, caused FutureFuel to incur approximately $12 million of realized derivative losses during April. The impact of that event can clearly be seen in our results today. We have since amended our derivative strategy to help protect against this basis risk exposure and mitigate against the impacts of any recurrence of those market conditions. The outlook for our biodiesel segment now looks strong for the balance of the year.
We are increasingly encouraged by developments in our Chemicals segment. As well as various active projects to bring new products to our site, we have added the manufacturing capability to meet the requirements of the FDA Current Good Manufacturing Practice (CGMP) regulations. This will open up additional opportunities to our company, particularly in the field of pharmaceutical intermediates,” said Tom McKinlay, Chief Executive Officer for FutureFuel Corp.
2022 Cash Dividends
FutureFuel paid a regular quarterly cash dividend in the amount of $0.06 per share on our common stock in the second quarter of 2022. The remaining quarterly dividends of $0.06 per share are expected to be paid in September and December.
Financial Overview and Key Operating Metrics
Financial and operating metrics, which include non-GAAP financial measures, include dollars in thousands, except per share amounts:
Certain Financial and Operating Metrics (Unaudited)
Three Months Ended June 30, Dollar % 2022 2021 Change Change Revenue $ 117,796 $ 74,118 $ 43,678 59 % Loss from operations $ (1,515 ) $ (2,003 ) $ 488 24 % Net (loss) income $ (3,104 ) $ 3,481 $ (6,585 ) n/a (Loss) earnings per common share: Basic $ (0.07 ) $ 0.08 $ (0.15 ) n/a Diluted $ (0.07 ) $ 0.08 $ (0.15 ) n/a Adjusted EBITDA $ 18,709 $ 4,668 $ 14,041 301 % Six Months Ended June 30, Dollar % 2022 2021 Change Change Revenue $ 160,057 $ 115,634 $ 44,423 38 % Loss from operations $ (11,122 ) $ (15,061 ) $ 3,939 26 % Net loss $ (15,502 ) $ (5,292 ) $ (10,210 ) (193 %) Loss per common share: Basic $ (0.35 ) $ (0.12 ) $ (0.23 ) (192 %) Diluted $ (0.35 ) $ (0.12 ) $ (0.23 ) (192 %) Adjusted EBITDA $ 20,807 $ (3,157 ) $ 23,964 n/a
Financial and Business Summary
Consolidated sales revenue in the three and six months ended June 30, 2022 increased $43,678 and $44,423 compared to the three and six months ended June 30, 2021. These increases resulted from increased sales price in the biofuels segment, and to a lesser extent, from increased prices in the chemicals segment. The increase was partially reduced by lower sales volumes in biofuels for both the three-and six-month periods and from lower sales volumes in the chemical segment in the three-month period ending June 30, 2022.
Loss from operations in the three months ended June 30, 2022 improved $488 compared to the three months ended June 30, 2021. This improvement primarily resulted from increased margins from the biofuels segment. Mostly offsetting this increase was the change in the activity in derivative instruments with a loss of $17.5 million in the current three-month period, as compared to $5.4 million in the same period of 2021. We experienced unprecedented volatility in the heating oil futures market which resulted in losses that were not fully recoverable on fuel sold. We have amended our derivative execution strategy to help mitigate reoccurrence.
Loss from operations in the six months ended June 30, 2022 improved $3,939 compared to the six months ended June 30, 2021. This improvement primarily resulted from increased margins from biofuels and the prior year period exorbitantly high natural gas prices experienced in the February 2021 Winter Storm Uri. Mostly offsetting this increase was the change in the activity in derivative instruments with a loss of $26.6 million in the current six-month period as compared to $8.0 million in the same period of 2021.
Capital expenditures were $1,895 in the first six months of 2022, compared with $488 in the same period in 2021.
Cash and Cash Equivalents and Marketable Securities
Cash and cash equivalents and marketable securities totaled $168,580 as of June 30, 2022, compared with $184,711 as of December 31, 2021.
FutureFuel is a leading manufacturer of diversified chemical products and biofuels. FutureFuel's chemicals segment manufactures specialty chemicals for specific customers (“custom chemicals”) as well as multi-customer specialty chemicals (“performance chemicals”). FutureFuel’s custom manufacturing product portfolio includes proprietary agrochemicals, adhesion promoters, a biocide intermediate, and an antioxidant precursor. FutureFuel’s performance chemicals products include a portfolio of proprietary nylon and polyester polymer modifiers and several small-volume specialty chemicals and solvents for diverse applications. FutureFuel’s biofuels segment primarily produces and sells biodiesel to its customers. Please visit www.futurefuelcorporation.com for more information.
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements deal with FutureFuel’s current plans, intentions, beliefs, and expectations, and statements of future economic performance. Statements containing such terms as “believe,” “do not believe,” “plan,” “expect,” “intend,” “estimate,” “anticipate,” and other phrases of similar meaning are considered to contain uncertainty and are forward-looking statements. In addition, from time-to-time FutureFuel or its representatives have made or will make forward-looking statements orally or in writing. Furthermore, such forward-looking statements may be included in various filings that the company makes with United States Securities and Exchange Commission (the “SEC”), in press releases, or in oral statements made by or with the approval of one of FutureFuel’s authorized executive officers.
These forward-looking statements are subject to certain known and unknown risks and uncertainties, including, but not limited to the COVID-19 pandemic and the response thereto, as well as assumptions that could cause actual results to differ materially from those reflected in these forward-looking statements. Factors that might cause actual results to differ include, but are not limited to, those set forth under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in FutureFuel’s Form 10-K Annual Report for the year ended December 31, 2021 and in its future filings made with the SEC. An investor should not place undue reliance on any forward-looking statements contained in this document, which reflect FutureFuel management’s opinions only as of their respective dates. Except as required by law, the company undertakes no obligation to revise or publicly release the results of any revisions to forward-looking statements. The risks and uncertainties described in this document and in current and future filings with the SEC are not the only ones faced by FutureFuel. New factors emerge from time to time, and it is not possible for the company to predict which will arise. There may be additional risks not presently known to the company or that the company currently believes are immaterial to its business. In addition, FutureFuel cannot assess the impact of each factor on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. If any such risks occur, FutureFuel’s business, operating results, liquidity, and financial condition could be materially affected in an adverse manner. An investor should consult any additional disclosures FutureFuel has made or will make in its reports to the SEC on Forms 10-K, 10-Q, and 8-K, and any amendments thereto. All subsequent written and oral forward-looking statements attributable to FutureFuel or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements contained in this document.
Non-GAAP Financial Measures
In this press release, FutureFuel used adjusted EBITDA as a key operating metric to measure both performance and liquidity. Adjusted EBITDA is a non-GAAP financial measure. Adjusted EBITDA is not a substitute for operating income, net income, or cash flow from operating activities (each as determined in accordance with GAAP), as a measure of performance or liquidity. Adjusted EBITDA has limitations as an analytical tool, and should not be considered in isolation or as a substitute for analysis of results as reported under GAAP. FutureFuel defines adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization expenses, excluding, when applicable, non-cash share-based compensation expense, public offering expenses, acquisition-related transaction costs, purchase accounting adjustments, loss on disposal of property and equipment, gains or losses on derivative instruments, other non-operating income or expense. Information relating to adjusted EBITDA is provided so that investors have the same data that management employs in assessing the overall operation and liquidity of FutureFuel’s business. FutureFuel’s calculation of adjusted EBITDA may be different from similarly titled measures used by other companies; therefore, the results of its calculation are not necessarily comparable to the results of other companies.
Adjusted EBITDA allows FutureFuel’s chief operating decision makers to assess the performance and liquidity of FutureFuel’s business on a consolidated basis to assess the ability of its operating segments to produce operating cash flow to fund working capital needs, to fund capital expenditures, and to pay dividends. In particular, FutureFuel management believes that adjusted EBITDA permits a comparative assessment of FutureFuel’s operating performance and liquidity, relative to a performance and liquidity based on GAAP results, while isolating the effects of depreciation and amortization, which may vary among its operating segments without any correlation to their underlying operating performance, and of non-cash stock-based compensation expense, which is a non-cash expense that varies widely among similar companies, and gains and losses on derivative instruments, whose immediate recognition can cause net income to be volatile from quarter to quarter due to the timing of the valuation change in the derivative instruments relative to the sale of biofuel.
A table included in this earnings release reconciles adjusted EBITDA with net income, the most directly comparable GAAP performance financial measure, and a table reconciles adjusted EBITDA with cash flows from operations, the most directly comparable GAAP liquidity financial measure.
Condensed Consolidated Balance Sheets
(Dollars in thousands)
(Unaudited) June 30, 2022 December 31, 2021 Assets Cash and cash equivalents $ 129,154 $ 137,521 Accounts receivable, inclusive of the blenders' tax credit of $13,084 and $8,232 and net of allowances for bad debt of $87 and $67, respectively 37,566 29,374 Inventory 31,584 26,920 Marketable securities 39,426 47,190 Other current assets 15,113 14,828 Total current assets 252,843 255,833 Property, plant and equipment, net 79,145 82,901 Other assets 5,398 5,596 Total noncurrent assets 84,543 88,497 Total Assets $ 337,386 $ 344,330 Liabilities and Stockholders’ Equity Accounts payable, inclusive of the blenders' tax credit rebates due customers of $890 and $890, respectively $ 42,051 $ 22,823 Dividends payable 5,252 - Other current liabilities 13,513 12,233 Total current liabilities 60,816 35,056 Deferred revenue – long-term 12,046 16,755 Other noncurrent liabilities 1,718 3,591 Total noncurrent liabilities 13,764 20,346 Total liabilities 74,580 55,402 Preferred stock, $0.0001 par value, 5,000,000 shares authorized, none issued and outstanding - - Common stock, $0.0001 par value, 75,000,000 shares authorized, 43,763,243, issued and outstanding at June 30, 2022 and December 31, 2021 4 4 Accumulated other comprehensive income 61 178 Additional paid in capital 282,443 282,443 Retained earnings (accumulated deficit) (19,702 ) 6,303 Total Stockholders’ Equity 262,806 288,928 Total Liabilities and Stockholders’ Equity $ 337,386 $ 344,330
Condensed Consolidated Statements of Operations
and Comprehensive Income
(Dollars in thousands, except per share amounts)
Three Months Ended
Six Months Ended
2022 2021 2022 2021 Revenue $ 117,796 $ 74,118 $ 160,057 $ 115,634 Cost of goods sold and distribution 116,819 74,161 166,235 126.413 Gross profit (loss) 977 (43 ) (6,178 ) (10,779 ) Selling, general, and administrative expenses 1,737 1,162 3,510 2,710 Research and development expenses 755 798 1,434 1,572 Total operating expenses 2,492 1,960 4,944 4,282 Loss from operations (1,515 ) (2,003 ) (11,122 ) (15,061 ) Other (expense) income, net (2,527 ) 1,015 (6,022 ) 913 Loss before income taxes (4,042 ) (988 ) (17,144 ) (14,148 ) Income tax benefit (938 ) (4,469 ) (1,642 ) (8,856 ) Net (loss) income $ (3,104 ) $ 3,481 $ (15,502 ) $ (5,292 ) (Loss) earnings per common share Basic $ (0.07 ) $ 0.08 $ (0.35 ) $ (0.12 ) Diluted $ (0.07 ) $ 0.08 $ (0.35 ) $ (0.12 ) Weighted average shares outstanding Basic 43,763,243 43,754,232 43,763,243 43,748,768 Diluted 43,763,243 43,754,422 43,763,243 43,748,768 Comprehensive (loss) income Net (loss) income $ (3,104 ) $ 3,481 $ (15,502 ) $ (5,292 ) Other comprehensive (loss) income from unrealized net (loss) gain on available-for-sale debt securities (86 ) 60 (148 ) - Income tax effect 18 (16 ) 31 - Total other comprehensive (loss) income, net of tax (68 ) 44 (117 ) - Comprehensive (loss) income $ (3,172 ) $ 3,525 $ (15,619 ) $ (5,292 )
Consolidated Statements of Cash Flows
(Dollars in thousands)
Six Months Ended June 30, 2022 2021 Cash flows from operating activities Net loss $ (15,502 ) $ (5,292 ) Adjustments to reconcile net income to net cash from operating activities: Depreciation 5,276 5,231 Amortization of deferred financing costs 48 47 Benefit for deferred income taxes (1,672 ) (8,881 ) Change in fair value of equity securities 7,339 222 Change in fair value of derivative instruments (2,388 ) 1,136 (Gain) loss on the sale of investments 27 (758 ) Loss on disposal of property and equipment 50 - Impairment of intangible asset - 1,315 Noncash interest expense 17 16 Changes in operating assets and liabilities: Accounts receivable (8,172 ) (9,946 ) Accounts receivable – related parties (20 ) 1,405 Inventory (4,664 ) (19,625 ) Income tax receivable (20 ) 801 Prepaid expenses 1,773 1,977 Prepaid expenses – related parties (8 ) (12 ) Other assets 125 635 Accounts payable 19,171 23,074 Accounts payable – related parties 326 7,959 Accrued expenses and other current liabilities (659 ) 7 Accrued expenses and other current liabilities – related parties (1 ) - Deferred revenue (2,769 ) (1,318 ) Other noncurrent liabilities (187 ) (342 ) Net cash used in operating activities (1,910 ) (2,349 ) Cash flows from investing activities Collateralization of derivative instruments 383 (2,060 ) Purchase of marketable securities - (19,170 ) Proceeds from the sale of marketable securities 250 37,873 Proceeds from the sale of property and equipment 56 - Proceeds from the sale of intangible asset - 93 Capital expenditures (1,895 ) (488 ) Net cash (used in) provided by investing activities (1,206 ) 16,248 Cash flows from financing activities Proceeds from the issuance of stock - 231 Payment of dividends (5,251 ) (114,658 ) Net cash used in financing activities (5,251 ) (114,427 ) Net change in cash and cash equivalents (8,367 ) (100,528 ) Cash and cash equivalents at beginning of period 137,521 198,122 Cash and cash equivalents at end of period $ 129,154 $ 97,594 Cash paid for interest $ - $ 43 Cash paid for income taxes $ 276 $ 79 Noncash investing and financing activities: Noncash capital expenditures $ 95 $ 51 Noncash operating leases $ - $ 269
Reconciliation of Non-GAAP Financial Measure to Financial Measure
(Dollars in thousands)
Reconciliation of Adjusted EBITDA to Net Income
Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Net (loss) income $ (3,104 ) $ 3,481 $ (15,502 ) $ (5,292 ) Depreciation 2,706 2,623 5,276 5,231 Non-cash stock-based compensation - - - - Interest and dividend income (747 ) (790 ) (1,411 ) (1,795 ) Non-cash interest expense and amortization of deferred financing costs 33 31 65 63 Losses on disposal of property and equipment 44 - 50 - Losses on derivative instruments 17,476 5,404 26,605 8,029 Loss (gain) on marketable securities 3,239 (1,612 ) 7,366 (537 ) Other income - - - - Income tax benefit (938 ) (4,469 ) (1,642 ) (8,856 ) Adjusted EBITDA $ 18,709 $ 4,668 $ 20,807 $ (3,157 )
Reconciliation of Adjusted EBITDA to Net Cash Used in Operating Activities
Six Months Ended June 30, 2022 2021 Net cash used in operating activities $ (1,910 ) $ (2,349 ) Benefit for deferred income taxes 1,672 8,881 Interest and dividend income (1,411 ) (1,795 ) Income tax benefit (1,642 ) (8,856 ) Loss on derivative instruments 26,605 8,029 Change in fair value of derivative instruments 2,388 (1,136 ) Change in operating assets and liabilities, net (4,895 ) (4,615 ) Impairment of intangible asset - (1,315 ) Other - (1 ) Adjusted EBITDA $ 20,807 $ (3,157 )
Condensed Consolidated Segment Income
(Dollars in thousands)
Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Revenue Custom chemicals $ 12,266 $ 12,260 $ 27,981 $ 22,935 Performance chemicals 5,928 3,287 11,774 8,722 Chemicals revenue $ 18,194 $ 15,547 $ 39,755 $ 31,657 Biofuels revenue 99,602 58,571 120,302 83,977 Total Revenue $ 117,796 $ 74,118 $ 160,057 $ 115,634 Segment gross profit (loss) Chemicals $ 4,196 $ 4,285 $ 9,614 $ 2,984 Biofuels (3,219 ) (4,328 ) (15,792 ) (13,763 ) Total gross profit (loss) 977 (43 ) (6,178 ) (10,779 )
Depreciation is allocated to segment cost of goods sold based on plant usage. The total assets and capital expenditures of FutureFuel have not been allocated to individual segments as large portions of these assets are shared to varying degrees by each segment, causing such an allocation to be of little value.
- Revenues were $117.8 million, up 59% from $74.1 million